< Return
 

About Enzon

We are a biopharmaceutical company dedicated to the development of important medicines for patients with cancer.

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing important medicines for patients with cancer. Enzon's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform and the Locked Nucleic Acid (LNA) technology. Enzon's receives a royalty revenue stream from licensing partnerships for other products developed using the proprietary PEGylation technology.

Search

Enter your email address to sign up for the Enzon mailing list.


 
News
  • 02-09-2010

    Enzon to Release Fourth Quarte...

    Enzon to Release Fourth Quarter 2009 Earnings on Wednesday, February 17, 2010; Conference Call and Webcast to Follow

    click here for more information

  • 10-28-2009

    Enzon to Release Third Quarter...

    Enzon to Release Third Quarter 2009 Earnings on Tuesday, November 3, 2009; Conference Call and Webcast to Follow

    click here for more information

  • 07-27-2009

    Enzon to Release Second Quarte...

    Enzon to Release Second Quarter 2009 Earnings on Tuesday, August 4, 2009; Conference Call and Webcast to Follow

    click here for more information

  • 02-11-2008

    Enzon Pharmaceuticals to Add N...

    Enzon Pharmaceuticals to Add New Independent Director to Board

    click here for more information